Review
doi: 10.1016/s0735-1097(01)01534-0.
Doxazosin and congestive heart failure
Affiliations
- PMID: 11691497
- DOI: 10.1016/s0735-1097(01)01534-0
Item in Clipboard
Review
Doxazosin and congestive heart failure
J Am Coll Cardiol.
.
Free article
Abstract
Congestive heart failure (CHF) is the most devastating cardiac sequella of long-standing hypertension. Recent data from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) have shown the risk of CHF to be twice as high with doxazosin than with chlorthalidone. Although some questions remain regarding the diagnosis and mortality of CHF in the doxazosin arm and regarding the risk of dying from malignancy in the diuretic arm of ALLHAT, drugs used to treat hypertension should lower the CHF risk. Therefore, until ironclad safety data are provided, doxazosin, and probably all alpha-blockers, should no longer be used as first-line antihypertensive therapy.
Similar articles
-
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.JAMA. 2000 Apr 19;283(15):1967-75. JAMA. 2000. PMID: 10789664 Clinical Trial.
-
Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.Curr Hypertens Rep. 2000 Jun;2(3):241-2. doi: 10.1007/s11906-000-0005-3. Curr Hypertens Rep. 2000. PMID: 10981155 No abstract available.
-
Doxazosin and congestive heart failure.Congest Heart Fail. 2002 May-Jun;8(3):178-84. doi: 10.1111/j.1527-5299.2002.00939.x. Congest Heart Fail. 2002. PMID: 12045387 Review.
-
Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial.Cleve Clin J Med. 2000 Jun;67(6):429-33. doi: 10.3949/ccjm.67.6.429. Cleve Clin J Med. 2000. PMID: 10860225
-
What are the best first-line antihypertensives: answers and more questions from the ALLHAT study.Expert Opin Investig Drugs. 2003 May;12(5):879-85. doi: 10.1517/13543784.12.5.879. Expert Opin Investig Drugs. 2003. PMID: 12720498 Review.
Cited by
-
Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.Pharmacol Rev. 2013 Dec 24;66(1):308-33. doi: 10.1124/pr.112.007203. Print 2014. Pharmacol Rev. 2013. PMID: 24368739 Free PMC article. Review.
-
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.Circulation. 2008 Nov 25;118(22):2259-67. doi: 10.1161/CIRCULATIONAHA.107.762229. Epub 2008 Nov 10. Circulation. 2008. PMID: 19001024 Free PMC article. Clinical Trial.
-
Recent publications by ochsner authors.Ochsner J. 2002 Spring;4(2):122-3. Ochsner J. 2002. PMID: 21765753 Free PMC article. No abstract available.
-
Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism.Endocrine. 2024 Jul;85(1):99-121. doi: 10.1007/s12020-024-03751-1. Epub 2024 Mar 6. Endocrine. 2024. PMID: 38448679 Review.
-
Adrenergic blocker terazosin potentially suppresses acetaminophen induced-acute liver injury in animal models via CYP2E1 gene.Toxicol Res. 2022 Jan 11;38(3):323-330. doi: 10.1007/s43188-021-00116-y. eCollection 2022 Jul. Toxicol Res. 2022. PMID: 35874506 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
